PaLM Conf Minutes 2016-Dec-14

Back to IHE Pathology and Laboratory Medicine (PaLM) Domain

Back to IHE Pathology and Laboratory Medicine (PaLM)Technical Committee Page

Recording

The recording for this meeting can be downloaded HERE

Attendees

Francois Macary	Phast
Raj Dash, Co-Chair	CAP
Riki Merrick, Co-Chair	APHL
Carolyn Knapik	CAP, secretariat
Mary Kennedy	CAP, secretariat
Alessandro Sulis	CRS4
Dan Rutz	Epic
David de Mena	SAS
Dmytro Rud	Roche
Filip Migom	MIPS
Francesca Frexia	CRS4
JD Nolen	Cerner
Jurgen De Decker	MIPS
Laurent Lardin	bioMerieux
Megumi Kondo	Sakura Finetek Japan

Minutes

Agenda Review

1st hour

Announcement: Dmytro’s last meeting in PaLM – he is leaving Roche, staying in Healthcare, but not lab

 

F2F date for Japan: May 31 – June 2, 2017

 

Board report:

• Still need to find a few numbers for the connectathons – Megumi to look up registry numbers for Japan Riki to send this out to the google group

 

Call for new proposals:

• open until December 31^st, 2016 – will review all proposals on our January committee call

 

SET document review:

• Merged use cases between inter and intra-organizational organization transfer
• Will a single diagram be enough, or do we need to add a second diagram to describe the different actors in the lab that touch the specimen for custody tracking – do we keep the pre-/post-processors?
• Pre-and post-processor is not mandatory
• How do we show different kinds of devices – analyzer or pre-/ post-processor, so combine these devices into a single actor “Laboratory Device”, and remove the redundant events, once this is done. The distinction between Analyzer, Pre/post-processor is just textual information, and can also be carried in the metadata of the event.
• Specimen discharge and specimen archive (= post-processor)
• Re-identification –person collecting tissue has access to the patient info – in the lab create a new number for bio-banking number – keeping a link to the original patient ID – but others do NOT have that access. Sometimes the de-identification occurs later or in some cases it does not happen, when the sample is helped indefinitely – to identify if biobank tissue has additional information for the clinical case (e.g. if there is cancer in the biobank sample, then the biobanking event is canceled) – but at some point de-identification could become total.
• Need to decouple de-identification and re-identification – biobanking identifier vs clinical identifier – when each of these steps happen is described by the research protocol, everyone is different
• Store both container ID and biobanking ID – container IDs across shipping orgs may not be unique, so we need to track both – important that vendors support MORE THAN ONE ID per biobanking specimen
• Not in diagram, but have in text

 

APSR 2.0:

• Shared the example XML file by Gunter
• Procedure Step section tracks all procedures performed on specimen

 

Riki drops off at 10:00 AM ET

 

Next call is on January 11, same time.